What Melatol Treats: Main Uses and Benefits

Melatonin's primary therapeutic domain is in addressing conditions where functional stability becomes affected due to sleep-wake cycle disruptions. Its uses are relevant when supportive symptom management is appropriate for temporary physiological imbalance.

The medication is utilized to help manage sleep issues associated with: difficulty falling asleep (insomnia), jet lag, and sleep disturbances related to shift work. For patients experiencing symptoms related to systemic imbalance in their circadian rhythm, it may assist with supporting the alignment of the sleep-wake cycle and may assist in managing the time required for sleep onset.

The overall benefit is that it provides support that helps ease the overall symptom burden during difficult episodes by easing distress. The product is commonly used to help with increasing total sleep time and supporting general well-being during symptomatic phases.

“The primary use is related to symptomatic relief that helps patients cope more steadily with sleep fluctuations.”

Quick Fact: Relief for symptoms that interfere with daily functioning

Melatol's official eligibility is defined by regulatory guidelines based on age, health status, and reproductive considerations. Use is licensed for adults aged 55 years or over for primary insomnia and for adults experiencing jet lag. Specialized pediatric use, typically in children and adolescents aged 2 to 18, is also licensed for sleep disturbances associated with specific neurodevelopmental disorders like ADHD or ASD. For general use, the medicine is not established or recommended for children under 18.

Contraindicated Populations

The product is contraindicated for patients with known hypersensitivity to the active ingredient or excipients, including those with certain rare hereditary sugar disorders like LAPP lactase deficiency.

Restricted or Not Recommended Use

Use is generally not recommended in several high-risk groups due to a lack of sufficient clinical data or potential metabolic concerns. This includes women who are pregnant or breastfeeding, patients with a history of autoimmune diseases, and individuals with severe hepatic impairment (liver) or severe renal impairment (kidney). Caution should be applied to patients with epilepsy and non-severe renal impairment.

Interactions with other medicines and products

Melatol (melatonin) can interact with other medicinal products by affecting the body's metabolism of the drug (pharmacokinetic interactions) or by having combined effects (pharmacodynamic interactions).

Do Not Combine: The combination of Melatol with fluvoxamine should be avoided. Fluvoxamine is a strong inhibitor of the liver enzymes (CYP1A2 and CYP2C19) that metabolize melatonin, leading to a significant increase in melatonin concentration in the blood.

Use with Caution: Caution is advised when taking Melatol with other medicines that are known to inhibit the CYP1A2 enzyme, such as cimetidine, quinolones, oestrogens (in oral contraceptives or hormone replacement therapy), and 5- or 8-methoxypsoralen (MOP). These can increase melatonin levels, which may increase the risk of side effects.

Conversely, products that induce CYP1A2, such as carbamazepine and rifampicin, may reduce melatonin concentrations and potentially decrease its effectiveness. Cigarette smoking may also decrease melatonin levels.

Pharmacodynamic Interactions: Melatol may enhance the sedating effects of CNS depressants, including benzodiazepines (e.g., temazepam, diazepam) and non-benzodiazepine hypnotics (e.g., zolpidem, zopiclone). Co-administration can increase drowsiness and impair attention and coordination. Alcohol should not be taken with Melatol as it can reduce the drug's effectiveness on sleep.

How Melatol Works: Mechanism of Action

Melatol's primary mechanism involves acting as an agonist on two G-protein coupled receptors: Melatonin receptor type 1 ( MT1) and type 2 ( MT2). These receptors are concentrated in the Suprachiasmatic Nucleus (SCN), the brain's central pacemaker. Agonism at these receptors inhibits adenylyl cyclase, which leads to the suppression of intracellular signaling messengers like cyclic AMP (cAMP). This molecular signal dampens the SCN's alerting activity, thereby influencing the biological processes of phase-shifting and timing of the sleep-wake cycle . This receptor agonism also initiates a cascade promoting the controlled lowering of core body temperature, a physiological change that precedes the transition from the wakeful state.

Separately, Melatol exhibits a receptor-independent mechanism by acting as a scavenger of free radicals (Reactive Oxygen Species and Reactive Nitrogen Species). This activity reduces oxidative damage at the cellular level in both central and peripheral tissues.

How to Use Melatol: Administration Guidelines

The usage of Melatol (melatonin) focuses strictly on the practical details of administration, dosing, and scheduling.

---

Administration Scope

Element	Instruction
Route of Administration	The primary route is Oral (swallowing of tablets, capsules, or liquid), though certain regional standards also recognize Sublingual (under the tongue) use.
Standard Dosing Schedule	Dosing is typically Once Daily and is administered close to the intended bedtime, usually within a window of 30 minutes to 2 hours.
Labeled Dosing Ranges	Prolonged-release forms are commonly used at 2 mg once daily for specific adult indications. For jet lag, doses may range from 3 mg up to a maximum of 6 mg. General adult ranges found across various forms can range from 0.1 mg to 10 mg.
Timing Relative to Meals	Prolonged-release tablets must be taken after food. Immediate-release oral solutions and standard tablets are generally recommended to be taken 2 hours before or 2 hours after food to avoid absorption interference.

---

Procedural and Course Constraints

The use protocol includes specific handling rules to ensure the integrity of the dose. Prolonged-release tablets must be swallowed whole and must not be cut, crushed, or chewed.

For situations where a dose is missed, the missed dose should be skipped entirely, and the next dose should be taken at the usual scheduled time; a double dose must not be taken to compensate.

The typical course duration is designated as short-term; for example, prolonged-release forms are often used for a maximum of up to 13 weeks for insomnia, while jet lag treatment is limited to a maximum of 5 days of consecutive use. Dose adjustments are generally not recommended for patients with moderate or severe hepatic or severe renal impairment.

Research Evidence / Overview of Studies for Melatol (Melatonin)

---

Evidence for Use in Managing Circadian Rhythm Disruption (Jet Lag Syndrome)

The research into Melatol's active ingredient for jet lag primarily relies on systematic reviews and meta-analyses that consolidate findings from multiple, short-term, placebo-controlled clinical trials. These studies were generally used in research exploring how symptoms change over time in adult air travelers who had crossed five or more time zones. Studies reported measurements related to the alignment of the sleep-wake cycle during the study period. Findings describe patterns observed in the studies related to a more rapid sleep-wake cycle alignment during the critical initial adjustment period.

However, follow-up durations were limited, as the studies typically only monitored responses over defined time intervals of just a few days following arrival. Therefore, long-term effects are not fully established, and data for other traveler groups, such as those crossing fewer time zones, remain insufficient.

---

Evidence for Use in Managing Difficulty Falling Asleep (Primary Sleep-Onset Insomnia)

Melatol was studied for its role in managing difficulty falling asleep, an issue that may be associated with periods of heightened symptom activity. The evidence base includes numerous randomized controlled trials (RCTs) and comprehensive systematic reviews. These studies explored primary outcomes such as the time needed to fall asleep (Sleep Onset Latency or SOL) and outcomes related to systemic or functional imbalance.

Trials reported measurements of the time taken to fall asleep compared to placebo. Some meta-analyses described a pattern of modest shifts in sleep-onset time measurements. Findings regarding measurements of Total Sleep Time (TST) and the quality of sleep were reported to be less consistent or demonstrated smaller measured differences across the body of research.

---

Evidence in Specific Populations, Including Children and Adolescents

Specialized research has been conducted for sleep issues in populations such as children and adolescents with neurodevelopmental disorders. The outcomes monitored included TST and SOL. Studies reported that findings describe patterns observed in the studies where an increase in total sleep duration and a reduction in the time to fall asleep was observed in some studies. However, the evidence is limited by the fact that the results apply only to the populations studied. The research field noted high variability in the specific doses and formulations used across different trials, which complicates broad generalization of findings.

---

Research Gaps and Areas of Uncertainty

Scientific reviewers have consistently identified limitations in the research landscape. The evidence quality varies across studies, and findings were mixed for certain secondary outcomes. Sample sizes were modest in many of the initial trials, meaning the results apply only to the specific populations studied. Key limitations include limited information for long-term outcomes, and questions remain regarding the optimal and consistent administration timing that may best influence outcomes related to systemic or functional imbalance.

Key Studies & References MedlinePlus, Melatonin

Common questions about Melatol (FAQ)

Q: What is Melatol used for?

A: Melatol is primarily indicated for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients who are 55 years of age and older. It contains a compound that is structurally similar to a naturally occurring hormone.

Q: How does Melatol affect the body?

A: Research suggests the compound in Melatol may contribute to the regulation of the sleep-wake cycle. Studies have shown that it acts on specific receptors in the brain, which are understood to be involved in initiating and maintaining sleep.

Q: Is Melatol suitable for long-term use?

A: Evidence from clinical trials regarding long-term use of Melatol is limited. The current indication is for short-term treatment only. A healthcare provider can determine the appropriate duration of use.

Q: Can I stop taking Melatol abruptly?

A: Available clinical data do not suggest a risk of dependence or withdrawal symptoms upon discontinuing Melatol when used as indicated. However, any changes to a treatment regimen should always be discussed with a doctor.

How to Store and Dispose of Melatol?

Official regulatory guidelines define specific conditions for the storage and disposal of Melatonin (Melatol) to maintain product stability and ensure public safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Container	Keep in the original container and ensure it remains tightly closed to protect the medicine from moisture and light.
Child Safety	The product must be stored out of the reach and sight of children.

Disposal Instructions

Discard unused or expired Melatol according to local regulations. Do not flush the medication down the toilet or pour it into a drain unless specifically advised by a regulator. Use a formal medicine take-back program when available for proper disposal.